CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals (Checkmate), a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, today announced that it will present data at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago from April 14 – April 18. Data on Checkmate’s Phase 1b trial in subjects with advanced melanoma will be presented in an oral presentation in the Clinical Trials Plenary Session CTPL04 - Novel Immuno-oncology Strategies.
Oral Presentation Details:
Title: Intratumoral Toll-Like Receptor 9 (TLR9) Agonist, CMP-001,
In Combination With Pembrolizumab Can Reverse Resistance To PD-1
Inhibition In A Phase 1b Trial In Subjects With Advanced Melanoma
Abstract
No: 10610
Presentation Number: CT144
Date/Time:
April 17, 2018; 10:30 AM
Location: North Hall C, McCormick
Place North (Level 1)
About Checkmate
Checkmate Pharmaceuticals is a clinical
stage company leveraging its expertise in the field of CpG
oligonucleotides (TLR9 agonists) to specifically activate the innate arm
of the immune system to stimulate a systemic antitumor cytolytic T cell
(CTL) response. In combination with checkpoint inhibition, which blocks
the tumor’s ability to mute the immune response, Checkmate’s TLR9
agonist triggers a powerful CTL response to recognize and ultimately
destroy tumor cells.
Checkmate is a privately held company headquartered in Cambridge, MA.
Information regarding Checkmate is available at www.checkmatepharma.com.